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Avital L. Amir, Renate S. Hagedoorn, Simone A. P. van Luxemburg-Heijs,
ErikW. A. Marijt, Alwine B. Kruisselbrink, J. H. Frederik Falkenburg, Mirjam H. M. HeemskerkAfter HLA class I-mismatched stem cell transplantation, allo-HLA–directed CD8 T cell responses can be
activated without the help of CD4 T cells if memory CD8 T cells cross-reactive against the allo-HLA class
I are present or if na€ıve CD8 T cells are administered during inflammatory conditions. However, in the
absence of inflammatory conditions, cooperation between CD4 and CD8 T cells likely is required for an
effective primary CD8 T cell response directed against allo-HLA class I. In this study we investigated whether
a coordinated response of CD8 and CD4 T cells could be demonstrated in an HLA class I–directed immune
response in a patient who developed severe graft-versus-host disease (GVHD) after the administration HLA-
A2–mismatched donor lymphocyte infusion in the absence of inflammatory conditions. A previously admin-
istered donor lymphocyte infusion from the same donor did not lead to an immune response, excluding the
presence of a substantial pool of CD8 T cells cross-reactive against HLA-A2 within the memory T cell com-
partment of the donor. Analysis of isolated donor CD8 and CD4 T cell clones activated during the GVHD
revealed a polyclonal CD8 T cell response directed against the mismatched HLA-A2 and a polyclonal CD4
T cell response recognizing HLA-A2–derived peptides presented in HLA class II. In addition, leukemic blasts
present at the time of the emergence of GVHD expressed HLA-A2 and HLA class II and could activate both
the CD4 and CD8 alloreactive T cells. Our results demonstrate that the GVHD was mediated by a cooper-
ative CD4 and CD8 response directed against the mismatched HLA-A2 and suggest that leukemic blasts
possibly activated this CD8 and CD4 T cell response.
Biol Blood Marrow Transplant 18: 210-219 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: GVHD, HLA-mismatched stem cell transplantation, Allo-HLA directed immune response,
Coordinated immune response, HLA-derived peptides, AML blastINTRODUCTION
In vivo, naive CD8 T cells require priming by
activated antigen-presenting cells (APCs) to be able
to proliferate and differentiate to effector T cells.
APCs can be activated by the inflammatory signals
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6/j.bbmt.2011.10.018of inflammatory signals, CD4 T cells can activate
APCs through CD40–CD40L interaction and
cytokine production [3-5]. Thus, T cell responses
to noninflammatory immunogens require dual
recognition of antigen or antigen-expressing cells by
CD8 as well as CD4 T cells, which is thought to serve
as a safeguard against autoimmunity [6]. In contrast to
na€ıve CD8 T cells, memory CD8 T cells do not need
priming by activated APCs [7,8], indicating that CD4
T cells are not required for the effective activation of
memory CD8 T cell responses.
Allo-HLA reactive T cells involved in the genera-
tion of graft-versus-host disease (GVHD) and graft
rejection after HLA-mismatched stem cell transplan-
tation (SCT) can be derived from the na€ıve T cell
pool as well as the memory T cell pool [9]. As we
reported previously, allo-HLA reactivity exerted by
virus-specific T cells is common, suggesting that
many memory T cells are able to exert allo-HLA
reactivity [10]. Based on the lower activation threshold
Biol Blood Marrow Transplant 18:210-219, 2012 211Coordinated CD8 and CD4 T Cell Response Directed Against HLA Class Iof memory CD8 T cells, an allo-HLA class I–directed
immune response can be easily activated without the
presence of activated APCs and the help of CD4
T cells if T cells cross-reactive against the mismatched
HLA class I molecule are present within the memory
CD8 T cell compartment. If these CD8 T cells are
not present in the memory T cell pool, then the allo-
HLA directed immune response has to develop from
the na€ıve CD8 T cell compartment, which likely
requires activated APCs.
Before undergoing SCT, patients are treated with
conditioning regimens including irradiation and/or
chemotherapy that cause tissue damage, triggering
the production of proinflammatory cytokines and
thereby activating APCs [11]. In addition, SCT is
often complicated by infection, which can lead to sys-
temic inflammatory signals [12]. In the presence of
these inflammatory conditions, cooperation between
CD8 and CD4 T cells might not be required for effec-
tive activation of primary alloimmune responses, as
was demonstrated by Korngold and Sprent [13] and
Sprent et al. [14], who showed that in heavily irradiated
major histocompatibility complex class I mismatched
mice, purified CD8 T cells were able to initiate
GVHD without the help of CD4 T cells.
However, in the absence of tissue damage or infec-
tion, allogeneic cells are noninflammatory immuno-
gens. In this situation, cooperation between CD4
and CD8 T cells is likely required for an effective pri-
mary CD8 T cell response. Chakraverty et al. [15]
demonstrated that in delayed major histocompatibility
complex class I mismatched donor lymphocyte infu-
sion (DLI) not preceded by irradiation, CD4 T cells
were necessary for the expansion of GVHD-inducing
CD8 T cells. Because a coordinated response requires
CD4 and CD8 T cell activation by the same antigen-
expressing cells, allogeneic cells expressing both
HLA class I and HLA class II are necessary.
In the present study we investigated whether a co-
ordinated response of CD8 and CD4 T cells could be
demonstrated in a HLA class I directed immune
response in a patient with acute myelogenous leukemia
(AML) who underwent T cell–depleted SCT and
received 2 DLIs from the same HLA-A2–mismatched
donor. The first DLI did not produce an immune
response, indicating a lack of a substantial pool of
CD8 T cells cross-reactive against HLA-A2 within
the donor’s memory T cell compartment. The second
DLI administered in the presence of HLA class II–
positive leukemic cells led to a coordinated response
of CD8 and CD4 T cells that resulted in severe acute
GVHD. Characterization of the alloimmune response
leading to the GVHD showed that the CD8 T cell
response was directed against the mismatched HLA-
A2 molecule, and that the CD4 T cell response
recognized HLA-A2–derived peptides presented in
the context of theHLA-DR1molecule shared betweenpatient and donor. Patient leukemic cells present at the
time of emergence of GVHD expressed HLA-A2 and
HLA-DR and were able to activate both the CD8 and
CD4 alloreactive T cells, suggesting that the leukemic
blasts might have activated the coordinated CD8 and
the CD4 T cell response.PATIENTAND METHODS
Patient
The patient was a 55-year-old male with AML
secondary to myelodysplastic syndrome in complete
remission. After receiving a nonmyeloablative condi-
tioning regimen consisting of antithymocyte globulin,
fludarabine, and busulfan [16], he underwent T cell–
depleted SCT from a sibling donor. No immune sup-
pression was administered after transplantation. At 6
mo after undergoing SCT, he received a DLI of
2.5  106 T cells/kg for mixed chimerism. At 12
months after SCT, he received a second DLI contain-
ing 7.5*10e6 T cells/kg for AML. Five weeks after the
second DLI, the patient died of grade IV GVHD.
HLA typing was as follows: patient,A0201, A0301,
B0702, B3501, C0401, C0701, DRB1-0101, DRB1-
1501, DQB1-0501, DQB1-0602, DPB1-0402; donor,
A2601, A0301, B0702, B3501, C0401, C0701, DRB1-
0101, DRB1-1501, DQB1-0501, DQB1-0602, DPB1-
0402.
Cell Collection and Preparation
After informed consent was secured, peripheral
blood and bone marrow samples were obtained from
the patient and donor, as well as from other patients
and healthy donors. Mononuclear cells were isolated
by Ficoll-Isopaque separation and cryopreserved.
Stable Epstein-Barr virus (EBV)-transformed B cell
lines (EBV-LCLs) were generated using standard pro-
cedures. HLA-A21 donor EBV-LCLs were generated
by transduction of donor derived EBV-LCLs with
a retroviral vector encoding for HLA-A*0201 [17].
Fibroblasts were cultured from skin biopsy specimens
in Dulbecco’s modified Eagle’s medium with 1g/L
glucose (BioWhittaker, Verviers, Belgium) and 10%
FBS (BioWhittaker). Keratinocytes were cultured
from skin biopsy specimens in keratinocyte serum-
free medium supplemented with 30 mg/mL of bovine
pituitary extract and 2 ng/mL of epithelial growth
factor (Invitrogen, Carlsbad, CA).
Flow Cytometry
Anti–HLA-A2-FITC, anti–HLA-DR-APC, anti–
CD40-PE, anti–CD86-PE, anti–CD45-PerCp,
anti–CD3-APC, anti–CD33-APC, anti–CD80-PE,
anti–CD54-PE, and anti–CD11c-PE mAbs were
obtained from BD Biosciences (San Jose, CA).
212 Biol Blood Marrow Transplant 18:210-219, 2012A. L. Amir et al.Anti–CD4-PE, anti–CD8-PE, anti–CD19-PE, and
anti–CD14-PE mAbs were purchased from Caltag
(Carlsbad, CA). Anti–BDCA1-PE and anti–BDCA2-
FITCmAbs were obtained fromMiltenyi Biotec (Ber-
gisch Gladbach, Germany). The Beckman Coulter
TCR Vb Kit (Fullerton, CA) was used to analyze
TCR Vb usage of the CD4 T cell clones. Flow cytom-
etry analysis was performed on a BD flow cytometer.
Generation of Alloreactive T Cell Clones
Peripheral blood mononuclear cells (PBMCs)
were collected from the patient at the start of
GVHD, 3 weeks after the second DLI, in the absence
of administration of immunosuppressive drugs. The
PBMCs were stained with anti–HLA-A2, anti–HLA-
DR, anti-CD4, and anti-CD8mAbs at 4C for 30min-
utes and washed once. HLA-DR1 (activated) and
HLA-A22 (donor) CD41 or CD81T cells were sorted
with a single cell per well into U-bottom microtiter
plates containing 100 mL of feeder mixture consisting
of Iscove’s modified Dulbecco’s medium (Cambrex,
Rutherford, NJ), 5% FBS, 5% human serum, IL-2
(120 IU/mL; Novartis, Emeryville, CA), phytohemag-
glutinin (0.8 mg/mL; Murex Biotec, Dartford, UK),
and 50 Gy of irradiated allogeneic third-party PBMCs
(0.5  106/mL). Proliferating T cell clones were
selected and expanded further using nonspecific stim-
ulation and third-party feeder cells.
Characterization of T Cell Clones
Cytotoxicity assays and cytokine production assays
were performed to analyze the alloreactivity of the
expandedCD8T cell clones. In the cytotoxicity assays,
the CD8T cell clones were tested in a standard 4-hour
51Cr-release assay against patient EBV-LCLs, donor
EBV-LCLs, and third-party HLA-A21 and HLA-
A22 EBV-LCLs in an effector-to target (E:T) ratio
of 10:1. The cytokine production assays tested IFN-
g production of the CD8 T cells clones in response
to patient EBV-LCLs, donor EBV-LCLs, and third-
party HLA-A21 and HLA-A22 EBV-LCLs. To mea-
sure IFN-g production, 5000 T cells were cultured
with 20,000 stimulator cells in a final volume of
150 mL of Iscove’s modified Dulbecco’s medium sup-
plemented with 60 IU/mL of IL-2. After 18 hours of
incubation, supernatants were harvested, and IFN-g
production was measured by standard ELISA (CLB,
Amsterdam, The Netherlands). To examine the
HLA restriction of the CD8 T cell clones, blocking
studies were performed using BB7.2 (anti–HLA-A2),
W6.32 (anti-HLA class I), or B1.23.2 (anti-HLA-B
and C) mAbs. Patient EBV-LCLs, donor EBV-
LCLs, and donor EBV-LCLs transduced with HLA-
A22 and HLA-A21 EBV-LCLs were preincubated
with saturating concentrations of mAbs for 1 hour at
20C before the addition of T cells.To analyze the alloreactivity of the expanded CD4
T cell clones, IFN-g production in response to patient
EBV-LCLs and donor EBV-LCLs was tested. To
determine the HLA-restriction molecules of CD4
T cell clones, blocking studies were performed using
W6.32 (anti-HLA class I), PdV5.2 (anti-HLA class
II), B8.11.2 (anti–HLA-DR), SPV-L3 (anti–HLA-
DQ), or B7.21 (anti–HLA-DP) mAbs. Patient EBV-
LCLs, donor EBV-LCLs, and donor EBV-LCLs
transduced with HLA-A2 were preincubated with
saturating concentrations of mAbs for 1 hour at
room temperature before the addition of T cells. In
addition, the IFN-g production in response to a panel
of HLA-DR*01011HLA-A*02011, HLA-DR*01011
HLA-A*02012, HLA-DR*15011HLA-A*02011, and
HLA-DR*15011HLA-A*02012 EBV-LCLs was
tested. To identify the recognized HLA-A2–derived
peptide and the minimal recognized epitope of the
HLA-A2–derived peptide, IFN-g production of the
CD4 T cells clones in response to donor EBV-LCLs
loaded overnight with the different HLA-A2-derived
peptides was measured after 18 hours of coculture.
HLA-A2–Derived Peptides
To investigate epitopes of HLA-A*0201 that could
be recognized in the context of HLA class II by the
CD4 T cell clones, we created synthetic 20-mer
peptides covering the entire sequence of the HLA-
A*0201 molecule, with an overlap of 7 amino acids
between peptides, by solid-phase peptide synthesis.
To further analyze the minimal recognized epitope,
we generated truncated peptides of the recognized
region of amino acids 99-122 of the HLA-A2 mole-
cule. All peptides were checked for purity by analytic
reverse-phase HPLC and amino acid analysis.
Stimulatory Capacity of Patient Hematopoietic
Cells and Nonhematopoietic Cells
Bone marrow (BM) cells and PBMCs collected
from the patient before the first and second DLIs
were stained with anti–HLA-A2 mAb, and the HLA-
A21 cells from the 2 time points were selected by
a fluorescent-activated cell sorter. In addition, BM
cells collected from the patient before the second
DLI were stained with HLA-A2, CD33, and CD3
mAbs, and patient T cells (HLA-A21, CD31) and leu-
kemic cells (HLA-A21, CD331) were selected by
FACS. IFN-g production of the CD4 and CD8 clones
in response to the different T cell subsets was mea-
sured by ELISA. Recognition of nonhematopoietic
cells was analyzed using fibroblasts and keratinocytes
as stimulator cells. After cell culture of 3 days in
the presence or absence of 200 U/mL of IFN-g
(Immukine; Boehringer Ingelheim, Alkmaar, The
Netherlands), cells were thoroughly washed, and
10,000 stimulator cells were cocultured with 5000
Figure 1. Correlation of GVHD and donor CD4 and CD8 T cell activation. Patient (HLA-A21) and donor (HLA-A22) cells could be discriminated by
the expression of HLA-A2. HLA-DR expression characterizes the activated T cells. (A) PBMCs collected at 3 weeks before and after the DLI leading to
GVHD were stained with mAbs against CD3, HLA-A2, and HLA-DR. The gated CD31 cells are shown. After the DLI, the percentage of donor T cells
increased from 5% to 90%, and 70% of donor T cells were activated. (B) PBMCs collected during the GVHD were stained with anti–HLA-A2 and anti–
HLA-DR mAbs in combination with either anti-CD4 or anti-CD8. The gated CD4 and CD8 T cells are shown. Here 89% of the CD8 donor T cells and
40% of the CD4 donor T cells were activated.
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after overnight incubation.
RESULTS
CD8 and CD4 T Cells Activated During GVHD
after Single HLA Class I-Mismatched DLI
In this study we characterized the alloimmune re-
sponse in a patient experiencing GVHD after single
HLA class I-Mismatched DLI. Based on a crossover
analysis, the patient and donor had a disparity in
HLA-A2, with the other HLA class I and II molecules
matched completely. The patient received a T cell–
depleted SCT and was treated 6 months after the
SCT with DLI for mixed chimerism. No change in
chimerism was observed, and GVHD did not develop.
At 12 months after SCT, AML relapse occurred, with
9% blasts in bone marrow and 0.1%malignant cells in
peripheral blood, for which a secondDLI was given. In
contrast, the second DLI induced severe acute
GVHD, and chimerism analyses on BM-derived
mononuclear cells demonstrated a rapid change in pa-
tient chimerism from 41% before the second DLI to
2% after the second DLI (data not shown).
To investigate whether the occurrence of GVHD
correlated with activation of donor T cells, we
evaluated expression of the T cell activation marker
HLA-DR on donor T cells before and after the secondDLI by flow cytometry. The percentage of donor
T cells increased from 5% to 90% after the second
DLI, indicating strong T cell expansion. In addition,
70% of donor T cells were activated, as demonstrated
by high HLA-DR expression (Figure 1A). To investi-
gate whether both donor CD8 and CD4 T cells were
activated, we measured the expression of HLA-DR
on the CD8 and CD4 T cells during GVHD by flow
cytometry. As shown in Figure 1B, 89% of donor
CD8 T cells and 40% of donor CD4 T cells were
activated during GVHD.
Isolation of Alloreactive CD8 and CD4 T Cells
To characterize the CD8 and CD4 alloimmune re-
sponses, we isolated activated donor CD8 and CD4
Tcells frompatientPBMCscollectedduring theGVHD
by single cell sorting based on the expression of HLA-
DR and the absence of HLA-A2. Isolation and expan-
sion of these T cells resulted in 56 CD8 T cell clones
and 88 CD4 T cell clones for further analysis.
To investigate whether the CD8T cell clones were
alloreactive, we tested the clones for reactivity against
patient and donor EBV-LCLs. We found that 50 of
56 isolated CD8 clones were alloreactive, with cyto-
toxicity against patient EBV-LCLs but not against
donor EBV-LCLs (data not shown). In addition to
cytotoxicity, these 50 CD8 T cell clones also produced
IFN-g against patient EBV-LCLs, but not against
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Figure 2. Characterization of the HLA restriction and specificity of do-
nor CD8 and CD4 T cell clones isolated from the GVHD. (A) CD8 T cell
clones were tested for cytotoxicity against patient EBV-LCLs (pat-LCL),
donor EBV-LCLs (don-LCL), donor EBV-LCLs transduced with HLA-A2
(don-LCL 1 A2), and a panel of 8 HLA-A21 EBV-LCLs, of which one is
shown (A2-LCL). During the 4-hour incubation, no (-), anti-HLA class I
(anti-class I), anti–HLA-A2 (anti-A2), or anti–HLA B/C (anti-B/C) mAbs
were present. All clones demonstrated HLA-A2–restricted reactivity.
Cytotoxicity of a representative clone (8.26) is shown. (B) CD4 T cell
clones were stimulated with patient EBV-LCLs (pat-LCL) and donor
EBV-LCLs (don-LCL) in the presence of no (-), anti–HLA-A2 (A2),
anti–HLA class I (I), anti–HLA-class II (II), anti–HLA-DR (DR), anti–
HLA-DQ (DQ), or anti–HLA-DP (DP) mAbs, and IFN-g production
was measured by ELISA. Fourteen of the 21 CD4 T cell clones were
HLA-DR–restricted. IFN-g production of a representative HLA-DR re-
stricted clone (4.12) is shown. (C ) The HLA-DR–restricted alloreactive
CD4 T cell clones were tested against patient EBV-LCLs (pat-LCL),
214 Biol Blood Marrow Transplant 18:210-219, 2012A. L. Amir et al.donor EBV-LCLs (data not shown). To determine the
alloreactivity of the CD4 T cell clones, we tested the
88 clones against patient and donor EBV-LCLs in cy-
tokine production assays. Twenty-one of the 88 CD4
clones were alloreactive, as demonstrated by IFN-g
production on stimulation with patient EBV-LCLs
but not with donor EBV-LCLs (data not shown).
Polyclonal CD8 Response Directed Against Allo-
HLA-A2
To determine the diversity of the CD8 allores-
ponse, we analyzed the TCR Vb usage of the 50 allor-
eactive CD8 T cell clones by flow cytometry with Vb
mAbs and sequencing of the CDR3 region of the
TCR Vb chains. The CD8 clones showed usage of at
least 13 different TCR Vbs, and all TCR Vb chains
had a different CDR3 sequence (data not shown), dem-
onstrating that all 50 CD8 T cell clones were of differ-
ent clonal origin, and that the CD8 response in the
patient was polyclonal.
To define the HLA restriction, we tested the CD8
T cell clones against patient EBV-LCLs, donor EBV-
LCLs, donor EBV-LCLs transduced with HLA-
A*0201, and a panel of 8 HLA-A*02011 EBV-LCLs
in combination with HLA-blocking mAbs. Figure 2A
shows recognition of a representative clone. Donor
EBV-LCLs transduced with HLA-A*0201 and the
panel of HLA-A*02011 EBV-LCLs, of which one is
shown, were recognized by all CD8T cell clones. Rec-
ognition of patient EBV-LCLs, donor EBV-LCLs
transduced with HLA-A*0201, and third-party HLA-
A*02011 EBV LCLs was blocked by HLA-A2 and
HLA class I mAbs, but not by HLA-B/C mAb. These
results demonstrate that all 50 alloreactive CD8 clones
were restricted to HLA-A*0201, the only mismatched
HLA allele between patient and donor.
Polyclonal CD4 Response Directed Against
HLA-A2–Derived Peptide Presented in HLA
Class II
To determine the diversity of the CD4 response,
we analyzed the TCR Vb usage of the alloreactive
CD4 T cell clones by flow cytometry. We found that
the 21 alloreactive CD4 T cells expressed at least 10
different TCR Vb chains (data not shown), indicatingdonor EBV-LCLs (don-LCL), and donor EBV-LCLs transduced with
HLA-A2 (don-LCL 1 A2) in the presence of no (-), anti–HLA class I
(class I), anti–HLA-class II (class II), or anti–HLA-DR (DR) mAbs. Thir-
teen of the 14 HLA-DR–restricted CD4 T cell clones showed recogni-
tion of patient EBV-LCLs as well as of donor EBV-LCLs transduced
with HLA-A2, and recognition could be blocked by anti–HLA-class II
and anti–HLA-DR mAbs. IFN-g production of a representative clone
(4.12) is shown. (D) CD4 T cell clones were stimulated with a panel of
HLA-DR11HLA-A21 (DR1 A2), HLA-DR11HLA-A22 (DR1), HLA-
DR151HLA-A21 (DR15 A2), and HLA-DR151HLA-A22 (DR15) EBV-
LCLs. IFN-g production of a representative clone (4.12) is shown. These
results indicate that 13 of the 21 alloreactive CD4 clones recognized an
HLA-A2–derived peptide presented in the context of HLA-DR1.
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Figure 3. Identification of the HLA-A2–derived peptide and of the minimal epitopes recognized by the CD4 T cell clones. (A) The alloreactive CD4
T cell clones that showed recognition of HLA-A21 donor EBV-LCLs were stimulated with donor EBV-LCLs loaded with different peptides covering the
whole HLA-A2 sequence. All tested clones, of which a representative clone (4.12) is shown, recognized amino acids 101-122 of the HLA-A2 molecule.
(B) To analyze the minimal recognized epitope, the CD4 T cell clones were stimulated with donor EBV-LCLs loaded with truncated peptides of the
recognized region. The clones can be divided into 3 groups based on their minimal epitope recognition. The first group, represented by clone 4.12,
showed recognition of the 15-mer epitope of amino acids 106-120 and the 17-mer epitope of amino acids 103-119. The second group, represented
by clone 4.79, showed recognition of amino acids 103-117. Clone 4.44 recognized the 14-mer epitope of amino acids 101-114.
Biol Blood Marrow Transplant 18:210-219, 2012 215Coordinated CD8 and CD4 T Cell Response Directed Against HLA Class Ithat the CD4 response was polyclonal as well. To de-
fine the HLA restriction, we tested the alloreactive
CD4 T cell clones against patient EBV-LCLs blocked
with different HLA mAbs. IFN-g production of 14 of
the 21 clones could be blocked by HLA class II and
HLA-DR mAbs, indicating HLA-DR restriction.
Figure 2B shows the recognition of patient EBV-
LCLs by a representative CD4 T cell clone.
To analyze whether the CD4 T cells recognized
an HLA-A2–derived peptide presented in HLA
class II, we tested the CD4 clones against donor EBV-
LCLs transduced with HLA-A*0201. Thirteen of the
14 HLA-DR–restricted alloreactive CD4 clones (one
of which is shown in Figure 2C) recognized donor
EBV-LCLs transduced with HLA-A*0201, and this
recognition could be blocked by HLA-class II and
HLA-DR mAbs, but not by HLA class I mAb. To
further analyze the HLA-DR restriction, we tested the
CD4 T cell clones against a panel of HLA-DR*01011
HLA-A*02011, HLA-DR*01011HLA-A*02012,
HLA-DR*15011HLA-A*02011, andHLA-DR*15011
HLA-A*02012 EBV-LCLs. All 13 CD4 T cell
clones recognizing donor EBV transduced with
HLA-A*0201 recognized the HLA-DR*01011HLA-
A*02011 EBV-LCLs. The recognition of a representa-
tive clone is shown in Figure 2D. These results
demonstrate that 13 of the 21 isolated CD4 clones rec-
ognized an HLA-A2–derived peptide presented in
HLA-DR1.
Eight of the 21 alloreactive CD4 T cell clones did
not recognize donor EBV-LCLs transduced withHLA-A*0201 (data not shown). Because these clones
produced only low amounts of IFN-g, we did not pur-
sue further characterization of their specificity.
To investigate which epitopes of HLA-A*0201
were recognized in the context of HLA-DR1, we
tested the CD4 T cell clones against donor EBV-
LCLs loaded with overlapping 20-mer peptides cover-
ing the whole sequence of the HLA-A*0201 molecule.
All 13 CD4 T cell clones recognizing donor EBV
transduced with HLA-A*0201, showed recognition
of sequence 101-122 derived from a hypervariable re-
gion of the HLA-A*0201 molecule. Three representa-
tive clones are shown in Figure 3A. To further analyze
the minimal recognized epitope, we tested the CD4
T cell clones against truncated peptides of the recog-
nized region. Based on the recognition pattern, the
CD4 clones could be subdivided into 3 groups
(Figure 3B). The first group, represented by clone
4.12, recognized the 15-mer epitope of aa 106-120
and the 17-mer epitope of aa 103-119. This group
covered 9 of the 13 HLA-DR1–restricted HLA-A2–
specific CD4 clones, which showed usage of at least
5 different TCR Vb chains. The second group, repre-
senting 3 clones with different TCRVb chains, includ-
ing clone 4.79, showed recognition of aa 105-117.
Clone 4.44 recognized the 14-mer epitope 101-114.
These results show that although the majority of the
CD4 T cell clones all recognize a peptide derived
from the same region of the HLA-A2 molecule, there
was diversity between the clones in minimal epitope
recognition.
Figure 4. The presence, HLA class II and CD11c expression, and stimulatory capacity of patient leukemic blasts. (A) To visualize leukemic blasts, BM
cells were stained with mAbs against HLA-A2 and CD33. At the time of the first DLI, no leukemic blasts could be detected, whereas at the time of the
second DLI, 9% leukemic blasts were present in BM. This percentage of leukemic blasts was confirmed by BM morphology (data not shown). (B) Patient
BM cells collected before the second DLI were stained with HLA-A2, CD33 mAbs, and either HLA class II or CD11c mAbs. Cells gated on HLA-A2 and
CD33 positivity are shown. The dashed lines represent the isotype controls, and the gray lines represent the expression of HLA class II on the leukemic
blasts. The leukemic blasts showed high expression of HLA class II and CD11c. (C) To investigate whether a GVL effect was also seen at the time of
GVHD, patient BM cells collected at 4 weeks after the second DLI were stained with mAbs against HLA-A2, CD33, and CD3. (D) Two CD8 clones
(8.53) and 2 CD4 clones (4.12 and 4.43) were stimulated with AML blasts (AML) or with HLA-A21 PBMCs deprived of the leukemic blasts
(A21-AML) from the time of the second DLI. The CD4 T cell clones recognized only the leukemic blasts, and the CD8 T cell clones recognized all
HLA-A21 cells.
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demonstrates a coordinated alloimmune response con-
sisting of a polyclonal CD8 response directed against
the mismatched HLA-A2, as well as a polyclonal
CD4 response directed against peptides derived from
the mismatched HLA-A2 molecule presented in
HLA class II.Patient Leukemic Blasts Possibly Mediated the
Crosstalk Between the CD4 and CD8 Responses
Because severe acute GVHD developed after ad-
ministration of the second DLI but no clinical signs
of GVHD were observed after the first DLI, we inves-
tigated whether a difference in the composition of the
patient’s hematopoietic compartment at the times of
the first DLI and the second DLI could explain the
difference in clinical outcome. Patient and donor
chimerism in different cell subsets was measured at
the 2 time points by flow cytometry using lineage-specific mAbs in combination with HLA-A2 mAb.
The only significant difference in the composition of
the patient’s hematopoietic compartment at the time
of the DLIs was the absence of leukemic blasts at the
first DLI and the presence of leukemic blasts at the
second DLI. High numbers of leukemic blasts in the
BM (Figure 4A) and low numbers of leukemic blasts
in the peripheral blood (data not shown) were present
at the time of the second DLI.
To investigate whether the leukemic blasts could
have activated both the CD8 and CD4 alloimmune re-
sponses, we determined the expression of HLA class II
in the patient’s leukemic blasts by flow cytometry. We
also evaluated the expression of costimulatory mole-
cules CD80, CD86, and CD40 and adhesion mole-
cules CD54 and CD11c, which also are involved in
immune response initiation. No expression of CD40,
CD80, CD86, or CD54 was found on leukemic cells
(data not shown); however, clear expression of HLA
class II and CD11c was observed (Figure 4A). The
Figure 5. The stimulatory capacity of cells derived from the nonhematopoietic compartment on donor CD4 and CD8 T cell clones. (A) Fibroblasts and
keratinocytes incubated for 3 days with or without IFN-gwere stained with HLA class II mAbs. The black and gray lines represent the keratinocytes and
fibroblasts with or without IFN-g pretreatment, respectively. The fibroblasts and keratinocytes expressed HLA class II only after pretreatment with
IFN-g. (B) CD4 and CD8 clones were stimulated with fibroblasts and keratinocytes derived from HLA-A21 HLA-DR11 individuals, preincubated
for 3 days with or without IFN-g. The CD8 clones (here represented by clone 8.53) recognized all HLA-A21 target cells. The CD4 clones recognized
fibroblasts and keratinocytes only after up-regulation of HLA class II with IFN-g. Some CD4 clones (represented by clone 4.12) showed strong recog-
nition, whereas other CD4 clones (represented by clone 4.43) showed weak recognition of the fibroblasts and keratinocytes preincubated with IFN-g.
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blood and bone marrow at the time of the second
DLI, consisting mostly of patient T cells (data not
shown), showed a marginal expression of HLA class
II and no expression of CD11c (Figure 4A).
Because GVHD and the graft-versus-leukemia
(GVL) effect are often associated, we investigated
whether the numbers of leukemic blasts was decreased
at the time of severe GVHD. The results, shown in
Figure 4C, demonstrate that the leukemic blasts com-
pletely disappeared from the bone marrow after the
second DLI at the time of GVHD, leaving only
some residual patient T cells present in bone marrow,
indicative for a GVL effect.
To investigate which cells were able to activate the
donor T cells, we tested different CD8 and CD4T cell
clones against the leukemic blasts and against the
HLA-A21 PBMCs deprived of the leukemic blasts.
The results demonstrate that the leukemic blasts
were the only cells in the patient’s hematopoietic com-
partment able to activate both the CD8 and CD4
T cell clones (Figure 4D).CD4 T Cells Can Recognize Nonhematopoietic
Cells in Inflammatory Conditions, Possibly
Enhancing GVHD
Given that the patient did not suffer from infec-
tions or GVHD at the time of the second DLI, HLA
class II expression of nonhematopoietic cells was
unlikely. However, to investigate whether during the
cytokine storm after development of GVHD, tissues
could be targets for both alloreactive CD8 and CD4T cells, we tested these T cell clones for recognition
of fibroblasts and keratinocytes derived from HLA-
A*02011HLA-DR*01011 individuals. A 3-day prein-
cubation of the fibroblasts and keratinocytes with
IFN-g was used to mimic inflammatory conditions.
As shown in Figure 5A, after pretreatment with
IFN-g, the fibroblasts and keratinocytes expressed
HLA class II. In agreement with this, the CD4 clones
recognized the fibroblasts and keratinocytes only after
up-regulation of HLA class II with IFN-g. Some of
these CD4 clones clearly recognized the fibroblasts
and keratinocytes after treatment with IFN-g, whereas
other CD4 clones demonstrated only minimal recog-
nition of HLA class II–expressing fibroblasts and
keratinocytes (Figure 5B). The CD8 clones (a repre-
sentative clone of which is shown in Figure 5B) recog-
nized all HLA-A21 target cells. These results indicate
that once the GVHD was initiated, the nonhemato-
poietic cells were able to serve as target cells for the
CD4 alloreactive T cells, thereby possibly amplifying
the graft-versus-host response.
DISCUSSION
In this study,wehave characterized the alloimmune
response in a patient suffering from GVHD after
an HLA-A2–mismatched DLI. A polyclonal CD8
response directed against the allo-HLA-A2 molecule
was found in conjunction with a polyclonal CD4 re-
sponse, of which a substantial part was directed against
HLA-A2–derived peptides presented in HLA-DR1.
The first DLI that the patient received did not lead
to an immune response, whereas the second DLI with
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dose of administered lymphocytes could explain the
difference in emergence of GVHD, given the correla-
tion between the occurrence of GVHD and the lym-
phocyte dose in DLI. Testing donor PBMCs against
patient PBMCs in a mixed lymphocyte reaction dem-
onstrated a very low frequency of alloreactivity
(\1:100,000). Thus, we assume that the difference in
DLI dose was too small to explain the difference be-
tween the complete absence of GVHD with the first
DLI dose and the development of lethal grade IV
GVHD with the second DLI dose. However, we can-
not completely rule out the possibility that the higher
T cell dose contributed to the emergence of GVHD
after the second DLI.
Based on the absence of an immune response after
the first DLI and the low frequency of alloreactive do-
nor cells measured in the mixed lymphocyte reaction,
we also conclude that there was not a substantial
pool of CD8 T cells cross-reactive against HLA-A2
within the donor’s memory repertoire. The DLIs
were administered long after the conditioning regimen
and in the absence of active infections, indicating that
no significant inflammatory conditions were apparent
around the time of emergence of GVHD.We hypoth-
esize that due to the absence of allo-HLA-A2 reactive
memory, CD8 T cells, and inflammatory conditions,
a coordinated response of CD8 and CD4 T cells di-
rected against the allogeneic HLA class I was required
for the development of GVHD.
In the immune response analyzed in this study, all
alloreactive CD8T cells were directed against the mis-
matchedHLA-A2, and themajority of the CD4T cells
recognized HLA-A2–derived peptides presented in
HLA class II, indicating that these HLA-A2–derived
peptides were abundantly expressed by the antigen-
presenting cells responsible for the initiation of the
response. The other CD4T cell clones most likely rec-
ognized peptides that were polymorphic between the
patient and the donor based on single nucleotide poly-
morphisms, termed minor histocompatibility anti-
gens, presented in HLA class II. HLA-derived
peptides are frequently presented in both HLA class
I and HLA class II [18,19], indicating that after
HLA-mismatched transplantation, the mismatched
HLA molecules also will be presented as peptides in
the context of self-HLA. Therefore, the common di-
rection of the CD8 and CD4 T cell responses against
allo-HLA-A2 suggests initiation of both responses by
the same HLA-A2 and HLA class II expressing cells.
The leukemic blasts were the only cells in patient
blood and bone marrow that highly expressed HLA
class II and HLA-A2 and were able to activate the
alloreactive CD8 as well as theCD4T cells, suggesting
a role for the leukemic blasts in initiating the
alloimmune response. Conversely, no expression of
costimulatory molecules, previously shown to be rele-vant for initiation of a primary immune response,
could be detected on the AML blasts. However,
AML cells express costimulatory molecules on activa-
tion [20,21], and these activated AML dendritic cells
(DCs) can induce autologous antileukemic reactive T
cells. In addition, it was recently shown that crosstalk
between CD41 T cells and leukemic cells in vivo can
change leukemic cells into an APC phenotype [22].
Thus, we postulate that a small part of the
allo-HLA–reactive T cells exhibiting high-avidity
allo-HLA reactivity can be activated in the absence
of costimulatory molecules and subsequently induce
expression of costimulatory molecules on AML cells,
which in turn activate the allo-HLA–reactive T cells
more broadly. Alternatively, the possibility that patient
DCs were still present in other tissues during the
secondDLI cannot be excluded.Merad et al. [23] dem-
onstrated that host Langerhans cells can self-renew
and thereby remain present in the skin for long periods
after allogeneic SCT. It is possible that Langerhans
cells and other tissue-resident DCs remained in the
patient posttransplantation and thus represented a ma-
jor priming population for the immune response lead-
ing to the GVHD. However, this would indicate that
patient DCs were also present at the time of the first
DLI, which did not lead to GVHD. Alternatively,
donor DCs might have cross-presented HLA-A2 pep-
tides. Lechler and coworkers [24,25] described cross-
presentation of HLA class I–derived peptide in HLA
class II by host APCs that migrated to the donor kid-
ney, thereby causing chronic graft rejection. But
because donor DCs were HLA-A22, the CD8 allores-
ponse could not have been initiated by these cells. Al-
though it has been demonstrated in vitro that DCs are
able to cross-present intactHLAmolecules, a phenom-
enon known as semidirect presentation [26], this has
not been demonstrated in vivo and is far less likely to
occur than direct presentation by patient APCs.
GVHD and GVL effects are often closely associ-
ated. Our patient demonstrated complete elimination
of AML blasts, indicative of a GVL effect at the time
of GVHD. The elimination of leukemia could have
been mediated by allo-HLA–reactive T cells that
recognize both malignant and healthy patient tissue
and thereby mediate both GVL and GVHD effects.
T cells selectively directed against the malignancy
also might have contributed to the GVL effect.
Separation of the GVHD/GVL-inducing and solely
GVL-inducing T cells may lead to the identification
of T cells directed against tumor-specific antigens,
useful for adoptive T cell therapy.
Although it was unlikely that nonhematopoietic
cells (which under normal conditions do not express
HLA class II) initiated the coordinated CD4 and
CD8 T cell response, up-regulation of HLA class II
molecules under inflammatory conditions during
GVHD might have amplified the effector phase of
Biol Blood Marrow Transplant 18:210-219, 2012 219Coordinated CD8 and CD4 T Cell Response Directed Against HLA Class Ithe immune response. As shown in Figure 5, some of
the alloreactive CD4 T cells could have been activated
by nonhematopoietic cells forced to express HLA class
II by culturing under conditions mimicking inflamma-
tion. We hypothesize that once GVHD was initiated,
activated T cells might have generated a cytokine
storm, leading to up-regulation of HLA class II on
nonhematopoietic cells and thereby increasing the
destruction of these cells.
Based on our findings, we conclude that the
GVHD emerging after a delayed HLA-A2–mis-
matched DLI was mediated by a cooperative CD4
and CD8 response directed against the mismatched
HLA-A2. We postulate that the CD8 T cells directed
against the allo-HLA-A2 molecule acted as the pri-
mary effector cells and thereby caused the majority
of tissue damage. We hypothesize that the
CD4 T cell response, directed mainly against HLA-
A2–derived peptide presented in HLA class II, was
essential for the initiation and possibly also the ampli-
fication of the response, and we speculate that the leu-
kemic blasts expressing HLA-A2 and HLA class II
might have activated both the CD8 and CD4
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